Whether filgotinib has been launched in China and related progress

Filgotinib is an oral small molecule targeted drug that selectively inhibits JAK1. It is mainly used to treat moderately to severely active rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) such as Crohn's disease. The drug was jointly developed by the Belgian company Galapagos and Gilead. It has been approved for the treatment of rheumatoid arthritis in Europe, Japan and other countries and regions, and is considered to be one of the more promising members of the JAK inhibitor family. However, as of now (2025), filgotinib has not yet received marketing approval from the National Medical Products Administration (NMPA) in mainland China, so domestic patients are temporarily unable to purchase the drug through formal channels.

Since it is not marketed in China, filgotinib is mainly obtained from overseas purchases. At present, many patients have chosen to purchase the drug from European, Japanese or Southeast Asian markets through cross-border medical services, overseas purchasing or relatives' assistance. It should be noted that purchasing drugs overseas involves risks such as legal compliance, customs clearance, and drug authenticity and safety. It is recommended that patients use it under the guidance of a doctor and choose reliable channels to obtain drugs to ensure drug safety.

In terms of price, the EU original research version of filgotinib (200mg×30 tablets) is priced higher, about It is RMB 110,000 to 1.210,000 yuan per box, which is a considerable financial burden for patients with chronic diseases who take medicine for a long time. In comparison, the generic version of filgotinib (100mg×30 tablets), the price is about 900 yuan, which is affordable and has become the choice of some patients. However, it should be noted that although generic drugs are similar in ingredients to original drugs, their production quality and regulatory environment cannot be completely equivalent to the original standards, and risks and costs need to be carefully weighed.

Overall, filgotinib is still in the unmarketed stage in China, and clinical data and marketing applications still need to be advanced. For patients, although they can currently only rely on overseas channels to obtain drugs, in the future, as the introduction of new international drugs accelerates, filgotinib may become an important player in the treatment field of JAK inhibitors in the Chinese market. It is recommended that patients pay close attention to drug approval developments and formulate scientific and reasonable treatment plans under the guidance of regular doctors.

Reference materials:https://www.drugs.com/